Biologics Contract Development Market Size, Share, Trends, and Growth Outlook

Biologics Contract Development Market is estimated to increase at a growth rate of 8.5% CAGR over the forecast period from 2024 to 2030.

 

The Biologics Contract Development Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Source (Mammalian, Microbial, Others), By Service (Cell Line Development, Process Development, Others), By Indication (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others).

 

An Introduction to Biologics Contract Development Market in 2024

The Biologics Contract Development market in 2024 serves as a critical enabler of biopharmaceutical innovation, offering specialized contract development and manufacturing services to biotechnology and pharmaceutical companies developing novel biologic drugs. Biologics contract development organizations (CDOs) provide expertise in cell line development, process optimization, analytical method development, and formulation studies to support the early-stage development of biologic therapeutics. By leveraging state-of-the-art technologies, regulatory expertise, and scalable manufacturing capabilities, CDOs enable biopharmaceutical companies to accelerate the translation of promising biologic drug candidates from concept to clinical testing. As the biopharmaceutical industry continues to expand its pipeline of biologics targeting diverse disease indications, the demand for contract development services is growing, driving investment and innovation in the biologics contract development market.

Biologics Contract Development Market Trend: Increasing Outsourcing of Biologics Development Services

A prominent trend in the Biologics Contract Development market is the increasing outsourcing of biologics development services by pharmaceutical and biotechnology companies. With the growing complexity of biologics drug development, including monoclonal antibodies, recombinant proteins, and gene therapies, many companies are seeking specialized expertise and infrastructure offered by contract development organizations (CDOs). Outsourcing enables companies to access state-of-the-art facilities, advanced technologies, and experienced scientific teams without significant capital investment, accelerating the development timelines and reducing overall costs.

Biologics Contract Development Market Driver: Demand for Specialized Expertise and Infrastructure

A key driver for the Biologics Contract Development market is the demand for specialized expertise and infrastructure required for biologics drug development. Unlike small molecule drugs, biologics necessitate unique manufacturing processes, including cell culture, fermentation, and purification, as well as stringent quality control measures to ensure product safety and efficacy. CDOs with established capabilities in bioprocessing, analytical testing, and regulatory compliance offer valuable resources and support to biopharmaceutical companies, enabling them to navigate the complexities of biologics development more efficiently and effectively.

Biologics Contract Development Market Opportunity: Expansion into Emerging Biologics Modalities and Markets

One potential opportunity in the Biologics Contract Development market is the expansion into emerging biologics modalities and markets. As the biopharmaceutical industry continues to innovate, novel biologics modalities such as cell and gene therapies, RNA-based therapeutics, and microbiome-based products are gaining traction for the treatment of various diseases. CDOs that can adapt and invest in specialized capabilities for these emerging modalities stand to capture significant market share and revenue growth. Additionally, expanding geographical presence into emerging markets with growing biologics development activities, such as Asia-Pacific and Latin America, can provide new avenues for business expansion and strategic partnerships.

 

Biologics Contract Development Market Segmentation

By Source

Mammalian

Microbial

Others

 

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

 

By Product

-MABs

-Recombinant proteins

-Others

Others

 

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Biologics Contract Development Market Companies

Abzena Ltd

AGC Biologics

Bionova Scientific Inc

BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)

Curia Global Inc

Fujifilm Diosynth Biotechnologies

Genscript

KBI Biopharma

STC Biologics

Thermo Fisher Scientific Inc

WuXi Biologics

*- List Not Exhaustive

 

Reasons to Buy the Biologics Contract Development Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Biologics Contract Development Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Biologics Contract Development Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Biologics Contract Development Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Biologics Contract Development Market Size Outlook, $ Million, 2021 to 2030

3.2 Biologics Contract Development Market Outlook by Type, $ Million, 2021 to 2030

3.3 Biologics Contract Development Market Outlook by Product, $ Million, 2021 to 2030

3.4 Biologics Contract Development Market Outlook by Application, $ Million, 2021 to 2030

3.5 Biologics Contract Development Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Biologics Contract Development Market Industry

4.2 Key Market Trends in Biologics Contract Development Market Industry

4.3 Potential Opportunities in Biologics Contract Development Market Industry

4.4 Key Challenges in Biologics Contract Development Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Biologics Contract Development Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Biologics Contract Development Market Outlook By Segments

7.1 Biologics Contract Development Market Outlook by Segments

By Source

Mammalian

Microbial

Others

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

-By Product

-MABs

-Recombinant proteins

-Others

Others

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

8 North America Biologics Contract Development Market Analysis And Outlook To 2030

8.1 Introduction to North America Biologics Contract Development Markets in 2024

8.2 North America Biologics Contract Development Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Biologics Contract Development Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Microbial

Others

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

-By Product

-MABs

-Recombinant proteins

-Others

Others

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

9 Europe Biologics Contract Development Market Analysis And Outlook To 2030

9.1 Introduction to Europe Biologics Contract Development Markets in 2024

9.2 Europe Biologics Contract Development Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Biologics Contract Development Market Size Outlook By Segments, 2021-2030

By Source

Mammalian

Microbial

Others

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

-By Product

-MABs

-Recombinant proteins

-Others

Others

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

10 Asia Pacific Biologics Contract Development Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Biologics Contract Development Markets in 2024

10.2 Asia Pacific Biologics Contract Development Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Biologics Contract Development Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Microbial

Others

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

-By Product

-MABs

-Recombinant proteins

-Others

Others

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

11 South America Biologics Contract Development Market Analysis And Outlook To 2030

11.1 Introduction to South America Biologics Contract Development Markets in 2024

11.2 South America Biologics Contract Development Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Biologics Contract Development Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Microbial

Others

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

-By Product

-MABs

-Recombinant proteins

-Others

Others

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

12 Middle East And Africa Biologics Contract Development Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Biologics Contract Development Markets in 2024

12.2 Middle East and Africa Biologics Contract Development Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Biologics Contract Development Market size Outlook by Segments, 2021-2030

By Source

Mammalian

Microbial

Others

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

-By Product

-MABs

-Recombinant proteins

-Others

Others

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

13 Company Profiles

13.1 Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Abzena Ltd

AGC Biologics

Bionova Scientific Inc

BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)

Curia Global Inc

Fujifilm Diosynth Biotechnologies

Genscript

KBI Biopharma

STC Biologics

Thermo Fisher Scientific Inc

WuXi Biologics

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Biologics Contract Development Market Segmentation

By Source

Mammalian

Microbial

Others

 

By Service

Cell Line Development

-Microbial

-Mammalian

-Others

Process Development

-Upstream

-Microbial

-Mammalian

-Others

-Downstream

-Impurity, isolation, & identification

-Physicochemical characterization

-Pharmaceutical analysis

-Others

 

By Product

-MABs

-Recombinant proteins

-Others

Others

 

By Indication

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)